Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | EBP | Q15125 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Heptane SCHEMBL241041 | 0.98 | EPHX1 (0.48) | EPHX1ALDH1A1EBPSIGMAR1TDP1 | |
| 1-Pentanol SCHEMBL28201262 | 0.90 | SMN1; SMN2 (0.46) | EPHX1ALDH1A1SMN1; SMN2RAB9AHSD17B10 | |
| 1-Hexanol SCHEMBL28200638 | 0.88 | ALDH1A1 (0.48) | EPHX1ALDH1A1EBPSIGMAR1TDP1 | |
| Propane SCHEMBL29260697 | 0.87 | — | — | |
| SCHEMBL28596158 | 0.87 | EPHX1 (0.35) | EPHX1ALDH1A1CYP1A2SMN1; SMN2RAB9A | |
| Butyl Alcohol SCHEMBL28856285 | 0.87 | ALDH1A1 (0.44) | EPHX1ALDH1A1SMN1; SMN2RAB9AHSD17B10 | |
| Bromide SCHEMBL28886830 | 0.86 | EPHX1 (0.34) | EPHX1SMN1; SMN2RAB9ANPC1TP53 | |
| SCHEMBL2473867 | 0.84 | NOS2 (0.35) | — | |
| SCHEMBL10067 | 0.84 | — | — | |
| SCHEMBL31673148 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023141155-A2 | DISTILLERS MEAL WITH REDUCED MYCOTOXIN LEVELS AND METHODS OF REDUCING MYCOTOXIN CONTAMINATION | NOVITA NUTRITION, LLC (US) | 2023-07-27 | — | — | WO | disclosed |
| US-8987377-B2 | Poly(amide) polymers for the delivery of oligonucleotides | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| CN-102731542-B | Preparation method of p-bromophenyl-boric acid | TAIZHOU CITY HWASUN PHARMACUETICAL AND CHEMICAL CO LTD | 2015-03-11 | — | — | CN | disclosed |
| EP-2491032-B1 | AKT INHIBITORS | LILLY CO ELI (US) | 2014-04-16 | — | — | EP | disclosed |
| US-20130253135-A1 | POLY(AMIDE) POLYMERS FOR THE DELIVERY OF OLIGONUCLEOTIDES | BANK OF AMERICA, N.A. | 2013-09-26 | — | — | US | disclosed |
| EP-2640400-A1 | POLY(AMIDE) POLYMERS FOR THE DELIVERY OF OLIGONUCLEOTIDES | Merck Sharp & Dohme Corp. (US) | 2013-09-25 | — | — | EP | disclosed |
| US-8436002-B2 | AKT inhibitors | ELI LILLY AND COMPANY (US) | 2013-05-07 | — | — | US | disclosed |
| CN-102731542-A | Preparation method of p-bromophenyl-boric acid | TAIZHOU CITY HWASUN PHARMACUETICAL AND CHEMICAL CO LTD | 2012-10-17 | — | — | CN | disclosed |
| EP-2491032-A1 | AKT INHIBITORS | Eli Lilly and Company (US) | 2012-08-29 | — | — | EP | disclosed |
| US-20120149684-A1 | AKT INHIBITORS | ELI LILLY AND COMPANY (US) | 2012-06-14 | — | — | US | disclosed |
| WO-2012068187-A1 | POLY(AMIDE) POLYMERS FOR THE DELIVERY OF OLIGONUCLEOTIDES | MERCK SHARP & DOHME CORP. (US) | 2012-05-24 | — | — | WO | disclosed |
| WO-2011050016-A1 | AKT INHIBITORS | ELI LILLY AND COMPANY (US) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130253135-A1 | POLY(AMIDE) POLYMERS FOR THE DELIVERY OF OLIGONUCLEOTIDES | PUF60, POLI, PARG | EPHX1 4721/4885ALDH1A1 4314/4885EBP 2208/4885 |
| US-20120149684-A1 | AKT INHIBITORS | AKT2, PIK3CA, AKT3 | EPHX1 3277/4885ALDH1A1 2866/4885EBP 1598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.